Topiramate for the Treatment of Binge Eating Disorder Associated With Obesity: A Placebo-Controlled Study

McElroy, Susan L.; Hudson, James I.; Capece, Julie A.; Beyers, Karen; Fisher, Alan C.; Rosenthal, Norman

doi:10.1016/j.biopsych.2006.08.008

Cited by 246 publications

(219 citation statements)

References 54 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…Preliminary studies indicate that BED occurs more frequently than either AN or BN (McElroy et al 2007). In the general population, BED prevalence estimates range from 1.5% to 5% in women and 1% to 3% in men (StriegelMoore and Franko 2003;Yanovski 1993).…”

Section: Obesity Is Associated With Disordered Eatingmentioning

confidence: 97%

Relevance of animal models to human eating disorders and obesity

2008

View full text Add to dashboard Cite

Background and rationale This review addresses the role animal models play in contributing to our knowledge about the eating disorders anorexia nervosa (AN) and bulimia nervosa (BN) and obesity. Objectives Explore the usefulness of animal models in complex biobehavioral familial conditions, such as AN, BN, and obesity, that involve interactions among genetic, physiologic, psychological, and cultural factors. Results and conclusionsThe most promising animal model to mimic AN is the activity-based anorexia rodent model leading to pathological weight loss. The paradigm incorporates reward elements of the drive for activity in the presence of an appetite and allows the use of genetically modified animals. For BN, the sham-feeding preparation in rodents equipped with a gastric fistula appears to be best suited to reproduce the postprandial emesis and the defects in satiety. Animal models that incorporate genes linked to behavior and mood may clarify biobehavioral processes underlying AN and BN. By contrast, a relative abundance of animal models has contributed to our understanding of human obesity. Both environmental and genetic determinants of obesity have been modeled in rodents. Here, we consider single gene mutant obesity models, along with models of obesigenic environmental conditions. The contributions of animal models to obesity research are illustrated by their utility for identifying genes linked to human obesity, for elucidating the pathways that regulate body weight and for the identification of potential therapeutic targets. The utility of these models may be further improved by exploring the impact of experimental manipulations on the behavioral determinants of energy balance.

show abstract

Section: Obesity Is Associated With Disordered Eatingmentioning

confidence: 97%

Relevance of animal models to human eating disorders and obesity

2008

View full text Add to dashboard Cite

show abstract

“…Current medications, like topiramate (McElroy et al, 2007;McElroy et al, 2009) or sibutramine (Appolinario et al, 2000;Wilfley et al, 2008), have been reported to reduce BE in clinical studies. However, their administration is associated with a variety of adverse side effects, which represent serious problems during chronic treatment (McElroy et al, 2009;Carter et al, 2003;Yager, 2008).…”

Section: Introductionmentioning

confidence: 99%

Role of Orexin-1 Receptor Mechanisms on Compulsive Food Consumption in a Model of Binge Eating in Female Rats

Piccoli

Bonaventura

Cifani

et al. 2012

Neuropsychopharmacol

144

102

View full text Add to dashboard Cite

Orexins (OX) and their receptors (OXR) modulate feeding, arousal, stress, and drug abuse. Neural systems that motivate and reinforce drug abuse may also underlie compulsive food seeking and intake. Therefore, the effects of GSK1059865, a dual OX 1 /OX 2 R antagonist were evaluated in a binge eating (BE) model in female rats. BE of highly palatable food (HPF) was evoked by three cycles of food restriction followed by stress, elicited by exposing rats to HPF, but preventing them from having access to it for 15 min. Pharmacokinetic assessments of all compounds were obtained under the same experimental conditions used for the behavioral experiments. Topiramate was used as the reference compound as it selectively blocks BE in rats and humans. Dose-related thresholds for sleep-inducing effects of the OXR antagonists were measured using polysomnography in parallel experiments. SB-649868 and GSK1059865, but not JNJ-10397049, selectively reduced BE for HPF without affecting standard food pellet intake, at doses that did not induce sleep. These results indicate, for the first time, a major role of OX 1 R mechanisms in BE, suggesting that selective antagonism at OX 1 R could represent a novel pharmacological treatment for BE and possibly other eating disorders with a compulsive component.

show abstract

“…2 Topiramate has been recognized as a drug that can induce memory and cognitive impairment in doses effective for the treatment of epilepsy. 3 Topiramate has been proposed for the treatment of some psychiatric disorders, such as alcohol abuse, 4 bulimia and bingeeating disorder 5 and, more recently, borderline personality disorder (BPD) 6 and posttraumatic stress disorder (PTSD). 7 Borderline personality disorder can be included in the new proposed category of overconsolidational spectrum disorders 8 since it is associated with child abuse and neglect.…”

Section: Introductionmentioning

confidence: 99%